Why the alarmin axis matters: TSLP and IL-33 as upstream disease drivers
Thymic stromal lymphopoietin (TSLP) and IL-33 are epithelial-derived cytokines that sit at the earliest point in the inflammatory cascade driving severe asthma — upstream of the eosinophil-dependent effector cytokines IL-5, IL-4, and IL-13 that most approved biologics target. Both are released by bronchial epithelial cells in response to aeroallergens, respiratory viruses, environmental pollutants, and physical airway stress, and both act on dendritic cells, mast cells, innate lymphoid cells (ILC2s), and T helper 2 (Th2) cells to orchestrate the downstream eosinophilia, IgE synthesis, and mucus hypersecretion that define severe asthma pathology.
The mechanistic distinction between TSLP and IL-33 is clinically important. TSLP signals through a heterodimeric receptor complex — TSLPR (also designated CRLF2) paired with IL-7Rα — expressed on dendritic cells and ILC2s. IL-33, by contrast, signals via the ST2/IL-1RAcP receptor complex and occupies an even earlier position in the danger-signalling hierarchy: it is a nuclear chromatin-associated cytokine that functions as an alarmin, released upon cell damage rather than through regulated secretion. This places IL-33 at the intersection of innate immune sensing and adaptive immune amplification, and means it is activated by a broader set of epithelial injury signals than TSLP alone.
Alarmins are endogenous molecules released by damaged or stressed cells that activate innate immune responses. In the asthma context, TSLP, IL-33, and IL-25 function as epithelial alarmins — they signal tissue damage to the immune system and initiate the type 2 inflammatory cascade before antigen-specific adaptive immunity is engaged. Blocking alarmins therefore interrupts inflammation at its source, rather than downstream of established immune activation.
Group 2 innate lymphoid cells (ILC2s) are the critical cellular effectors linking both TSLP and IL-33 alarmin signalling to downstream type 2 inflammation, particularly in allergen-naïve and steroid-resistant asthma contexts. ILC2s express both TSLPR/IL-7Rα and ST2, making them exquisitely sensitive to both alarmins simultaneously. This shared effector cell population is one reason why TSLP and IL-33 blockade produce overlapping — but not identical — clinical effects, and why bispecific co-blockade is attracting early-stage IP interest.
TSLP signals through the TSLPR/IL-7Rα heterodimeric receptor complex expressed on dendritic cells and ILC2s, while IL-33 signals via the ST2/IL-1RAcP receptor complex. Both alarmins converge on ILC2s as the primary effector cell, making them mechanistically complementary rather than redundant targets in severe asthma.
Critically, both alarmins are upstream of the eosinophil-generating cytokine IL-5. This is the scientific foundation for the commercial claim that anti-alarmin biologics should work across both eosinophil-high and eosinophil-low asthma phenotypes — a claim that has been validated for tezepelumab in Phase 3 data and that GSK’s SWIFT program is designed to replicate for depemokimab. According to data published in the New England Journal of Medicine, tezepelumab demonstrated exacerbation reduction in patients with blood eosinophil counts below 150 cells/μL — the most challenging-to-treat eosinophil-low subpopulation.
The competitive landscape: four molecules, two pathways, one label goal
Four biologics currently define the anti-alarmin competitive space in severe asthma, split across the TSLP and IL-33 pathways. Each molecule has a distinct molecular engineering strategy, clinical program design, and commercial positioning — but all four are oriented toward the same regulatory goal: a label that does not require a minimum eosinophil count for patient eligibility.
Tezepelumab (AstraZeneca/Amgen) is the reference molecule in the anti-TSLP class. It is a fully human IgG2λ monoclonal antibody that binds TSLP and prevents interaction with its receptor complex. The NAVIGATOR Phase 3 trial established tezepelumab as the first biologic approved for severe asthma without an eosinophil threshold requirement — the pivotal commercial differentiator that set the benchmark for every subsequent anti-alarmin program. Clinical subgroup data from NAVIGATOR demonstrated efficacy in patients with baseline fractional exhaled nitric oxide (FeNO) below 25 ppb and blood eosinophils below 300 cells/μL, as well as in oral corticosteroid-dependent patients enrolled in the SOURCE trial.
On the IL-33 pathway, itepekimab (Regeneron/Sanofi, REGN3500) is a fully human IgG4 anti-IL-33 antibody. Clinical data signals efficacy in eosinophil-high, former-smoker, and oral corticosteroid-dependent populations, though phenotype-agnostic efficacy equivalent to tezepelumab has not been confirmed for itepekimab in published data. Astegolimab (Genentech/Roche) is a second anti-IL-33 antibody with a distinct epitope relative to itepekimab; its SOLSTICE Phase 3 trial was designed without an eosinophil entry requirement, signalling Roche’s intent to pursue a broad label — though primary SOLSTICE data were not available at the time of this analysis.
Tezepelumab (AstraZeneca/Amgen) is the first biologic approved for severe asthma without an eosinophil threshold requirement, with Phase 3 NAVIGATOR trial data demonstrating exacerbation reduction in patients with blood eosinophil counts below 150 cells/μL — the most challenging-to-treat eosinophil-low subpopulation.
A fifth molecule, tozorakimab (AstraZeneca), is an anti-IL-33 antibody appearing in early-phase clinical data primarily in acute respiratory distress, heart failure with preserved ejection fraction (HFpEF), and COPD exacerbation — signalling an IP strategy to extend IL-33 blockade beyond chronic asthma into acute and cardiopulmonary indications. This cross-indication portfolio approach creates both opportunity and freedom-to-operate complexity as multiple assignees file overlapping claims across indication-specific uses of anti-IL-33 antibodies, as documented by WIPO patent filings in this space.
Track the full anti-TSLP and anti-IL-33 patent landscape across all assignees in real time.
Explore the alarmin patent landscape in PatSnap Eureka →Depemokimab’s half-life engineering and the twice-yearly dosing race
Depemokimab (GSK3511294) is not simply another anti-TSLP antibody — it is an engineering argument that half-life extension, not binding mechanism, will be the decisive competitive differentiator in the anti-alarmin space. The molecule is an IgG4 monoclonal antibody targeting TSLP, engineered with the YTE triple mutation (Met252Tyr/Ser254Thr/Thr256Glu) in the Fc region. These three point mutations enhance neonatal Fc receptor (FcRn) binding at endosomal pH, slowing lysosomal degradation and extending serum half-life to enable twice-yearly subcutaneous dosing.
“Depemokimab’s picomolar affinity for TSLP — with a KD below 1 pM — combined with YTE-mediated half-life extension enables a 6-month dosing interval that no currently approved anti-alarmin biologic in severe asthma can match.”
GSK patent filings describe depemokimab’s binding epitope on the TSLP molecule as overlapping with, but distinct from, the TSLPR interface — a characterisation that serves both a therapeutic function (effective receptor blockade) and an IP differentiation function (distinct from tezepelumab’s epitope). This dual-purpose epitope strategy is a recurring motif in next-generation biologic patent estates: the binding footprint is simultaneously a pharmacological claim and a freedom-to-operate argument.
GSK patent claims covering depemokimab combine YTE Fc engineering, anti-TSLP binding epitope characterisation, and low-volume subcutaneous formulation enabling 6-monthly dosing. This layered IP strategy — molecular engineering + binding site + formulation — creates a compound patent estate that is substantially harder to design around than a single-claim antibody composition patent.
The SWIFT Phase 3 program enrolled patients across eosinophil strata — including subgroups with blood eosinophils at or above 150, at or above 300, and below 300 cells/μL — to generate phenotype-spanning evidence. Phase 3 data from SWIFT, published in the New England Journal of Medicine by O’Brien and colleagues from GSK, indicated statistically significant exacerbation rate reduction. GSK’s clinical program is simultaneously building post-hoc biomarker responder data while demonstrating biomarker-agnostic benefit — the dual evidence package required for a broad label and a precision-medicine follow-on positioning strategy.
The half-life engineering direction is not unique to GSK. Regeneron patent filings describe half-life-extended anti-IL-33 formats using similar Fc engineering approaches, signalling that extended dosing intervals are becoming a standard competitive expectation across the anti-alarmin class — analogous to how long-acting formulations transformed the inhaled corticosteroid and long-acting beta-agonist markets. According to research published in Frontiers in Immunology, YTE and related Fc mutations have been validated across multiple therapeutic antibody programs as a reliable strategy for achieving two- to fourfold half-life extension without altering antigen-binding affinity or Fc effector function.
The eosinophil-low phenotype: why it is the decisive commercial battleground
Eosinophil-agnostic labelling is the single most consequential regulatory milestone in the severe asthma biologic market, and the competitive race to achieve it defines the strategic positioning of every anti-alarmin program. Earlier biologics targeting downstream effectors — anti-IL-5 agents mepolizumab and benralizumab, and the anti-IL-4Rα agent dupilumab — require minimum eosinophil counts or elevated type-2 biomarkers (FeNO, periostin) for patient eligibility, which structurally excludes a substantial proportion of severe asthma patients.
Anti-TSLP and anti-IL-33 biologics target upstream epithelial alarmins that drive both eosinophilic (type-2-high) and non-eosinophilic inflammation in severe asthma. This upstream mechanism of action is the scientific basis for pursuing regulatory approval without a minimum blood eosinophil count — a label designation that significantly expands the addressable patient population relative to anti-IL-5 and anti-IL-4Rα biologics.
The mechanistic rationale for phenotype-agnostic efficacy rests on the non-redundancy of TSLP and IL-33 with the eosinophil-generating cytokine IL-5. Because TSLP and IL-33 sit upstream of IL-5 in the signalling cascade, their blockade attenuates not only eosinophilic inflammation but also the neutrophilic and mixed-granulocyte asthma phenotypes that are driven by viral infection, occupational exposures, and non-allergic triggers. TSLP appears more dominant in allergen-driven and atopic asthma, while IL-33 — as a damage-associated alarmin released by cell lysis — may be more operative in viral-exacerbated and non-atopic disease. This mechanistic non-redundancy supports the commercial case for both target classes simultaneously.
“TSLP is more dominant in allergen-driven and atopic asthma; IL-33 may be more operative in viral-exacerbated and non-atopic disease — a mechanistic non-redundancy that supports the commercial case for both target classes and creates a scientific rationale for bispecific or combination approaches in mixed-driver patients.”
The biomarker landscape for patient stratification is also evolving beyond the eosinophil count. Academic literature and patent applications describe development of multi-analyte panels combining soluble ST2 (sST2), TSLP, periostin, FeNO, and blood eosinophils to stratify patients for specific alarmin-targeted therapies. Soluble ST2 — the decoy receptor shed from cell surfaces that binds IL-33 and prevents ST2/IL-1RAcP signalling — has been proposed as a pharmacodynamic biomarker for anti-IL-33 therapy, with elevated sST2 levels potentially reflecting IL-33 pathway activity. Research published in the American Journal of Respiratory and Critical Care Medicine by Wechsler and colleagues characterised sST2 as a candidate pharmacodynamic biomarker in this context.
GSK’s clinical program for depemokimab is designed around demonstrating biomarker-agnostic benefit while simultaneously building post-hoc biomarker responder datasets — a dual evidence strategy that positions depemokimab for both a broad label at approval and a precision-medicine follow-on narrative for post-approval market access discussions. This approach mirrors the tezepelumab playbook from AstraZeneca, which enrolled NAVIGATOR without an eosinophil floor and then generated subgroup analyses demonstrating consistent efficacy across all eosinophil strata.
Map biomarker patent filings and clinical stratification strategies across the severe asthma biologic pipeline.
Search severe asthma biomarker patents in PatSnap Eureka →Bispecifics, biomarkers, and the next IP wave in alarmin targeting
Single-alarmin blockade is the current clinical standard, but patent filings already signal the next competitive wave: bispecific antibodies designed to co-neutralise TSLP and IL-33 simultaneously, combination regimens pairing upstream alarmin blockade with downstream eosinophil-depleting agents, and inhaled anti-TSLP formats for topical lung delivery.
Bispecific TSLP × IL-33 constructs appear in patent filings using CrossMab, DVD-Ig, and knobs-into-holes Fc engineering platforms to achieve dual neutralisation. The scientific rationale, as described in retrieved patent claims, is that upstream co-blockade of two non-redundant alarmin pathways may provide additive or synergistic efficacy in patients with mixed inflammatory drivers — for example, patients with both allergen-driven atopic disease (TSLP-dominant) and frequent viral exacerbations (IL-33-dominant). These filings are at preclinical stages based on the absence of clinical data citations, but their existence signals that originators anticipate a post-approval competitive environment where single-alarmin blockade will be commoditised.
IL-33 exists in full-length and protease-cleaved mature forms. Full-length IL-33 has reduced ST2-activating potency relative to the cleaved mature form. Some anti-IL-33 antibodies in development neutralise only mature cleaved IL-33, while others neutralise both full-length and processed forms — a distinction with clinical relevance in allergen-driven (lower protease activity) versus neutrophil-driven, protease-rich asthma phenotypes. Epitope selection therefore has phenotype-stratification implications beyond simple binding affinity.
Combination regimens pairing anti-TSLP with anti-IL-5/IL-5Rα agents (mepolizumab, benralizumab) are also appearing in investigator-initiated and industry-sponsored protocols. The rationale is that patients with both elevated eosinophils and evidence of alarmin-driven non-eosinophilic disease may benefit from simultaneous upstream and downstream blockade. No Phase 3 combination trial results appear in the current dataset, but the combination hypothesis is consistent with the mechanistic non-redundancy of TSLP/IL-33 and IL-5 pathways.
Small molecule approaches — including JAK1/JAK2 inhibitors targeting downstream TSLP signalling, and siRNA-based IL-33 silencing constructs — appear at preclinical or early discovery stages in the patent and academic literature. Inhaled anti-TSLP nanobody/VHH formats designed for topical lung delivery appear in early patent filings, representing a potential route to higher local drug concentrations with reduced systemic exposure. The PatSnap Insights platform tracks these emerging modalities across the full global patent corpus, enabling R&D teams to monitor freedom-to-operate risks as the bispecific and small-molecule wave develops.
Bispecific antibodies designed to co-neutralise TSLP and IL-33 simultaneously — using CrossMab, DVD-Ig, and knobs-into-holes Fc engineering platforms — are appearing in patent filings at the preclinical stage, signalling that the next IP wave in severe asthma alarmin targeting will move beyond single-pathway blockade toward dual-alarmin co-neutralisation strategies.
For IP strategists, the cross-indication expansion of IL-33 blockade into acute respiratory distress, HFpEF, and COPD exacerbation — driven by AstraZeneca’s tozorakimab program — creates freedom-to-operate complexity as multiple assignees file overlapping claims across indication-specific uses of anti-IL-33 antibodies. Patent landscape monitoring across EPO and global filings is essential for organisations developing in this space, given the density of overlapping claims from at least five major pharmaceutical assignees (GSK, AstraZeneca, Regeneron, Roche/Genentech, and multiple undisclosed assignees in bispecific formats) documented in the retrieved dataset.